Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

GSK plc (GSK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,599.00 +15.50    +0.98%
19/04 - Closed. Currency in GBP ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BN7SWP63 
SEDOL:  BN7SWP6
  • Volume: 4,228,959
  • Bid/Ask: 1,538.00 / 1,650.00
  • Day's Range: 1,564.50 - 1,600.00
GSK plc 1,599.00 +15.50 +0.98%

LON:GSK Financials

 
A brief overview of the LON:GSK financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Glaxo over time.

GSK plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was GBP 8,147 million compared to GBP 7,829 million a year ago. Net income was GBP 1,464 million compared to GBP 10,821 million a year ago. Basic earnings per share from continuing operations was GBP 0.361 compared to GBP 0.188 a year ago. Diluted earnings per share from continuing operations was GBP 0.356 compared to GBP 0.186 a year ago. Basic earnings per share was GBP 0.361 compared to GBP 2.685 a year ago. Diluted earnings per share was GBP 0.356 compared to GBP 2.647 a year ago.For the nine months, sales was GBP 22,276 million compared to GBP 21,948 million a year ago. Net income was GBP 4,578 million compared to GBP 13,461 million a year ago. Basic earnings per share from continuing operations was GBP 1.13 compared to GBP 0.736 a year ago. Diluted earnings per share from continuing operations was GBP 1.114 compared to GBP 0.725 a year ago. Basic earnings per share was GBP 1.13 compared to GBP 3.345 a year ago. Diluted earnings per share was GBP 1.114 compared to GBP 3.297 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GSK Income Statement

Gross margin TTM 72.34%
Operating margin TTM 27.71%
Net Profit margin TTM 16.25%
Return on Investment TTM 24.71%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 8052 8147 7178 6951
Gross Profit 5237 5904 5279 5043
Operating Income 1639 2556 2051 1769
Net Income 350 1464 1624 1490

GSK Balance Sheet

Quick Ratio MRQ 0.55
Current Ratio MRQ 0.88
LT Debt to Equity MRQ 106.05%
Total Debt to Equity MRQ 135%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 59005 60862 59461 58596
Total Liabilities 46210 48243 47302 47284
Total Equity 12795 12619 12159 11312

GSK Cash Flow Statement

Cash Flow/Share TTM 1.66
Revenue/Share TTM 7.44
Operating Cash Flow  15.17%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3196 2212 1307 53
Cash From Investing Activities 268 -491 -964 -408
Cash From Financing Activities -3592 -1762 31 -318
Net Change in Cash -162 -18 317 -704
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GSK Comments

Write your thoughts about GSK plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mar 23, 2024 6:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My first experience with the Investor's Online was not great, I didn't received honest and open advice from those investor's, during my transfer process I wasn't informed of the progress all the way, from the few weeks I started investing through online, All the consultants I have ever dealt with have been friendly and i was introduce to this man whom is very helpful and efficient, Thank you sir. his waspp ÷195/1367/6556........ 0550500502020205005000686886686886686686868686868686886868686868866863535353535355335353555359090909909090090909090909090909009090900909090909090909090909090901010101001011010011010101010101011010100101010101010101011001010101010645454845454878754845454875454875454545454845754875487548754548754548454845454554545454875454545454545555888787545487545454422121221222454544544575787548454545454555151212121212422445544554455454544545545544555454554555455454515151515115454545454521121215844448484884848484848454888
private investor
private investor Mar 14, 2023 7:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
as of 14 Mar 23, anyone buy or sell? and why
Dec 12, 2022 10:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
my client wants to buy a young politician willing to deprive her country and then franchise a new store for the washing machines foundation
Nick Williams
Nick Williams Dec 07, 2022 9:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zantac case ruled in GSK favour, hence the rise
Amrit Sachdeva
Amrit Sachdeva Dec 07, 2022 9:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good
Giuseppe Giannachi
Giuseppe Giannachi Dec 07, 2022 3:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow...
Chemsedine Bendaci
Chemsedine Bendaci Jan 22, 2022 9:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
target price 2290£ according to zone bourse
Oct 07, 2021 2:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1st malaria vaccine approved by WHO. hopefully good news for the stock. definitely good for the developing world!
new age
new age Oct 07, 2021 2:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
who the f dislikes that! lol
Lucas Whipps
Lucas Whipps Sep 28, 2021 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Been In GSK since February and wearing almost a 15% gain which i'm pretty chuffed about , not sure what you guys think about GSK going into the future but i'm pretty happy with these returns and am thinking about investing in a PRE IPO called SpectrumX which i have seen on the homepage of LSE and the Sunday times. SpectrumXare leaders in proprietary formulations of HOCL, so looks promising for the future of pharmaceuticals. Have not dabbled with Pre IPOS so wanted to see what you guys think?
MoonBoi Skooma
MoonBoi Aug 13, 2021 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to the moon!
doc gramps
doc gramps Aug 13, 2021 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when?!
MoonBoi Skooma
MoonBoi Aug 13, 2021 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Already mooned now buy back at 1300
Mike Bamber
Mike Bamber Jul 28, 2021 7:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good old GSK. Never fails to disappoint.
Mark Silva
Mark Silva Jul 28, 2021 7:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
AMAZING....great news, good earnings...it comes +2% to -0.7%....I`m done, I`m out
Old Timer
Old Timer Jul 28, 2021 7:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As i said before this company does not understand competitive performance - radical change needed - one off hitting earnings forecast does not mean anything
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email